Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2013-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df9aba59c027625e94714e0bfca4f616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3de79084abaceee7ae83dcd49ec4866e |
publicationDate |
2013-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2013171289-A1 |
titleOfInvention |
Combination of cd37 antibodies with further agents |
abstract |
The present invention relates to immunotherapies that are based on depletion of CD37- positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/ patient using a combination of CD37 antibody /antibodies and bendamustine. The combination of CD37 antibodies, CD20 antibodies and bendamustine is shown to have a synergistic effect. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11466095-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108472361-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3302561-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IL-255532-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IL-255532-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11278629-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108472361-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11395796-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11104740-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2016276158-B2 |
priorityDate |
2012-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |